ACC patients with high expression of SLC7A11 exhibit increased sensitivity to certain anti-tumor drugs (YK-4-279, tozasertib, docetaxel, vinblastine and so on), suggesting an important role for SLC7A11 in the treatment of ACC patients. This evidence concerns the gene SLC7A11 and adrenal cortex carcinoma.